1P-LSD

From PsychonautWiki
Jump to: navigation, search
Summary sheet: 1P-LSD
1P-LSD
1P-LSD.svg
Chemical Nomenclature
Common names 1P-LSD
Substitutive name 1-Propionyl-d-lysergic acid diethylamide
Systematic name N,N-Diethyl-7-methyl-4-propanoyl-6,6a,8,9-tetrahydroindolo[4,3-fg]quinoline-9-carboxamide
Class Membership
Psychoactive class Psychedelic
Chemical class Lysergamide
Routes of Administration

WARNING: Always start with lower doses due to differences between individual body weight, tolerance, metabolism, and personal sensitivity. See responsible use section.



Oral
Dosage
Threshold Common Heavy
15 - 25 - 75 - 150 - 300 µg
Light Strong
Threshold 15 µg
Light 25 - 75 µg
Common 75 - 150 µg
Strong 150 - 300 µg
Heavy 300 µg +
Duration
Total 8 - 12 hours
Onset 20 - 60 minutes
Come up 45 - 120 minutes
Peak 3 - 5 hours
Offset 3 - 5 hours
After effects 6 - 24 hours









DISCLAIMER: PW's dosage information is gathered from users and resources for educational purposes only. It is not a recommendation and should be verified with other sources for accuracy.

1-Propionyl-d-lysergic acid diethylamide (also known as 1P-LSD) is a novel semi-synthetic psychedelic substance of the lysergamide class that produces LSD-like psychedelic effects when administered. It is structurally related to psychedelic lysergamides like LSD and ALD-52.

Along with ALD-52, 1P-LSD is theorized to act as a prodrug for LSD.[1] The similarities in chemical structure between 1P-LSD and LSD predicts a near-identical effect profile, likely differing mainly in its rate of absorption and duration. Anecdotal reports suggest this is the case, as most users claim to find them virtually indistinguishable from each other.

Very little data exists about the pharmacological properties, metabolism, and toxicity of 1P-LSD, and it has a very brief history of human usage. In the first few months of 2015, 1P-LSD began to be marketed as a legal alternative to LSD alongside lysergamides like ALD-52, ETH-LAD and AL-LAD and sold online as a research chemical.

As with LSD itself, 1P-LSD does not meet the criteria to be considered addictive or toxic by the scientific community.[2][3] Nevertheless, unpredictable adverse reactions such as anxiety, paranoia, delusions and psychosis are always liable to occur, particularly among those who are predisposed to mental disorders.[4] While these negative reactions or "bad trips" can often be attributed to factors like the user inexperience or improper preparation of set and setting, they have been known to happen among even highly experienced users as well. It is highly advised to approach this very potent, long-lasting hallucinogenic substance with the proper amount of preparation, and harm reduction practices if using it.

History and culture

1P-LSD first appeared as a research chemical sold by grey market vendors in January 2015.[5] Although it was likely discovered in an academic setting, it is unknown who first synthesized 1P-LSD, as the substance does not appear in any academic literature pre-dating its arrival on the research chemical market.[6] Interestingly, the future usage of 1-akylated lysergamide derivatives as a means to bypass controlled substance laws banning LSD as a precursor was foreseen in a DEA report from 1988:

Chemistry

Substitutive structure of a generic lysergamide molecule.

1P-LSD is a molecule of the lysergamide family. It is similar to LSD and is named for the propionyl group bound to the nitrogen of the polycyclic indole group of LSD. Propionyl consists of the carbonyl chain CH3CH2CO- bound to an amino group. 1P-LSD is homologous to ALD-52, which holds an acetyl group bound to the nitrogen instead of the propionyl group bound at the same location. The structure of 1P-LSD contains a polycyclic group featuring a bicyclic hexahydro indole bound to a bicyclic quinoline group. At carbon 8 of the quinoline, an N,N-diethyl carboxamide is bound.

Pharmacology

Further information: Serotonergic psychedelic

As with LSD, 1P-LSD likely acts as a partial agonist at the 5-HT2A receptor. The psychedelic effects are thought to primarily come from its efficacy at the 5-HT2A receptors distributed throughout the brain. It also likely displays binding activity at a wide range of monoamine receptors, such as those for dopamine and norepinephrine, due to the structural similarity it shares with LSD. However, the precise role of these interactions and how they result in the psychedelic experience require further investigation.

It has been theorized that 1P-LSD may act as a prodrug for LSD. While 1P-LSD shows only 38% the potency of LSD in mice, LSD is detected via LC-MS when 1P-LSD is incubated in human serum. Follow-up studies are currently being conducted to compare the affinity and selectivity of LSD and 1P-LSD at 5-HT receptors, and to determine whether 1P-LSD is hydrolyzed to LSD in vivo.[1] Otherwise, it is possible that 1P-LSD may be capable of exerting its own psychedelic effect.

Prior to the publishing of the above-cited research, medicinal chemist and psychedelic researcher David E. Nichols reportedly commented on the potential 1P-LSD serotonin receptor binding dynamics in private correspondence:[8]

Subjective effects

Anecdotal reports from many users suggest that the subjective effects of 1P-LSD are so similar to that of LSD so as to be virtually indistinguishable from one another. In comparison to other psychedelics such as psilocybin, LSA and ayahuasca, 1P-LSD is significantly more stimulating and fast-paced regarding the specific style of its physical and cognitive effects.

The effects listed below are based upon the subjective effects index and personal experiences of PsychonautWiki contributors. The listed effects should be taken with a grain of salt and will rarely (if ever) occur all at once, but heavier doses will increase the chances and are more likely to induce a full range of effects. Likewise, adverse effects become much more likely on higher doses and may include serious injury or death.

Physical effects
Child.svg

Visual effects
Eye.svg

Cognitive effects
User.svg

Multi-sensory effects
Gears.svg

Combinational effects

  • Cannabis - When used in combination with cannabis, both the visual and cognitive effects of 1P-LSD can be intensified and extended with extreme effectiveness. This should be used with extreme caution if one is not experienced with psychedelics, however, as this can also amplify the anxiety, confusion and psychosis producing aspects of cannabis significantly. If using this combination, users are advised to start off consuming only a fraction of their usual amount, spacing out hits, and waiting until the offset of the trip to avoid potentially being overwhelmed.
  • Dissociatives - When used in combination with dissociatives, the geometry, euphoria, dissociation and hallucinatory effects are often greatly enhanced. Dissociative-induced holes, spaces, and voids while under the influence of 1P-LSD have significantly more vivid visuals than dissociatives alone present, and more intense internal hallucinations, and corresponding confusion which can spontaneously manifest as delusions and psychosis.
  • MDMA - When used in conjunction with MDMA, the physical and cognitive effects of MDMA are amplified. The visual, physical and cognitive effects of 1P-LSD are also intensified to great euphoric heights manifested through uniquely pleasurable body highs and headspaces, and amazingly colorful and awe-inspiring visuals. The synergy between these substances is unpredictable, and it is best to start with markedly lower dosages than one would take for both substances individually. Additionally, users should be aware that there are reasons to believe that this combination may result in unforeseen neurotoxic effects, so a strong sense of caution and independent research are highly advised if one decides to experiment with this combination.[9][10][11]
  • Alcohol - This interaction is not typically recommended due to alcohol’s ability to cause dehydration and nausea which can negatively affect a trip if taken in moderate to high dosages. This combination is, however, reasonably safe in low doses and can often "take the edge off" a trip as well as dull its psychedelic effects in a fashion somewhat similar to benzodiazepines, albeit in a more physically stressful way.
  • Benzodiazepines - When used in combination with benzodiazepines, benzodiazepines can, depending on the dosage, slightly to completely reduce the intensity of the cognitive, physical and visual effects of an LSD trip. They are very efficient at stopping "bad trips" at the cost of amnesia and reduced trip intensity. Caution is advised when acquiring them for this purpose due to the very high addiction potential that benzodiazepines possess.
  • Psychedelics - When used in combination with other psychedelics, each substance's physical, cognitive and visual effects intensify and synergize strongly. The synergy between those substances is unpredictable, and for this reason generally not advised. If choosing to combine psychedelics, it is recommended to start with significantly lower dosages than one would take for either substance individually.

Experience reports

Anecdotal reports which describe the effects of this compound within our experience index include:

Additional experience reports can be found here:

Toxicity and harm potential

The toxicity and long-term health effects of recreational 1P-LSD use do not appear to have been studied in any scientific context and the exact toxic dose is unknown. This is because 1P-LSD is a research chemical with a very limited history of human use.

Anecdotal reports from user who have tried 1P-LSD suggests that there are no negative health effects attributed to simply trying it, by itself, at low to moderate doses, and using it very sparingly (although nothing can be completely guaranteed). Independent research should always be conducted to ensure that a combination of two or more substances is safe before consumption.

As with other psychedelic substances, there are relatively few physical side effects that have been reported associated with acute 1P-LSD exposure. Although no formal studies have been conducted, it is likely that as with LSD itself, 1P-LSD is able to be considered non-addictive, with an extremely low toxicity relative to dose.[12] It is also likely that as with LSD, there are little to no negative physical, cognitive, psychiatric or other toxic consequences associated with acute 1P-LSD exposure.

However, as with LSD and psychedelics in general, it is possible that 1P-LSD can act as a trigger for those with underlying mental disorders. Those with a personal or family history of mental illness are generally advised not to use this substance, particularly when outside of a supervised medical setting.

It is strongly recommended that one uses harm reduction practices when using this substance.

Tolerance and addiction potential

Although no formal studies have been conducted, it is assumed that like LSD itself 1P-LSD is not habit-forming and that the desire to use it can actually decrease with use.

Tolerance to the effects of 1P-LSD are built almost immediately after ingestion. After that, it takes about 5-7 days for the tolerance to be reduced to half and 14 days to be back at baseline (in the absence of further consumption). 1P-LSD presents cross-tolerance with all psychedelics, meaning that after the use of 1P-LSD all psychedelics will have a reduced effect.

Dangerous interactions

Although many psychoactive substances are safe to use on their own, they can become dangerous or even life-threatening when taken with other substances. The list below contains some potentially dangerous combinations, but may not include all of them. Certain combinations may be safe in low doses but still increase the possibility of injury of death. Independent research should always be conducted to ensure that a combination of two or more substances is safe before consumption.

The following substances are listed on the assumption that 1P-LSD possesses a similar if not the same dangerous interactions profile as LSD, and may include more due to its status as an unstudied research chemical.

  • Lithium - Individuals who take lithium for bipolar disorder or other psychiatric conditions should not take LSD and related lysergamides. There are numerous anecdotal reports of seizures and or unsafe psychosis from this combination.[13][14][15][16]
  • Stimulants - Combining stimulants with psychedelics may induce states of uncontrollable anxiety, over-stimulation, thought loops, and increase the risk of psychosis.[17]
  • Tramadol - Tramadol is known to lower the seizure threshold[18] and psychedelics may act as potential triggers for seizures among those who are susceptible.[19][20][21]

Legal status

1P-LSD is currently a gray area compound within many parts of the world. This means that it is not known to be specifically illegal within most countries, but people may still be charged for its possession under certain circumstances such as under analog laws and with the intent to sell or consume.

  • Austria: 1P-LSD is technically not illegal but it may fall in the NPSG (Neue-Psychoaktive-Substanzen-Gesetz Österreich) as an analogue of LSD, thus making it illegal to supply for human consumption.[22][23]
  • Germany: 1P-LSD is not listed under their controlled substance act.[citation needed]
  • Latvia: 1P-LSD is illegal in Latvia. Although it is not officially scheduled, it is controlled as an LSD structural analog due to an amendment made on June 1st, 2015.[24]
  • Sweden: Following its sale as a designer drug, 1P-LSD was made illegal in Sweden on 26 January 2016.[25]
  • Switzerland: 1P-LSD is illegal in Switzerland as of December 2015.[26]
  • United Kingdom: It is illegal to produce, supply, or import this drug under the Psychoactive Substance Act, which came into effect on May 26th, 2016.[27]
  • United States: Since 1P-LSD can be considered a prodrug for LSD, its possession and sale may be prosecutable in the United States under the Federal Analogue Act.

See also

External links

Discussion

Literature

  • Brandt, S. D., Kavanagh, P. V., Westphal, F., Stratford, A., Elliott, S. P., Hoang, K., ... & Halberstadt, A. L. (2016). Return of the lysergamides. Part I: Analytical and behavioural characterization of 1‐propionyl‐d‐lysergic acid diethylamide (1P‐LSD). Drug Testing and Analysis, 8(9), 891-902. https://doi.org/10.1002/dta.1884
  • Passie, T., Halpern, J. H., Stichtenoth, D. O., Emrich, H. M., & Hintzen, A. (2008). The Pharmacology of Lysergic Acid Diethylamide: A Review, 14, 295–314. https://doi.org/10.1111/j.1755-5949.2008.00059.x
  • Carhart-Harris, R. L., Muthukumaraswamy, S., Roseman, L., Kaelen, M., Droog, W., Murphy, K., … Nutt, D. J. (2016). Neural correlates of the LSD experience revealed by multimodal neuroimaging. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.1518377113

References

  1. 1.0 1.1 Brandt, S. D., Kavanagh, P. V., Westphal, F., Stratford, A., Elliott, S. P., Hoang, K., ... & Halberstadt, A. L. (2016). Return of the lysergamides. Part I: Analytical and behavioural characterization of 1‐propionyl‐d‐lysergic acid diethylamide (1P‐LSD). Drug Testing and Analysis, 8(9), 891-902. https://doi.org/10.1002/dta.1884
  2. Lüscher, C., & Ungless, M. A. (2006). The Mechanistic Classification of Addictive Drugs, 3(11). https://doi.org/10.1371/journal.pmed.0030437
  3. Nichols, D. E. (2016). "Psychedelics." Pharmacological Reviews, 68(2), 264-355. https://doi.org/10.1124/pr.115.011478
  4. Strassman, R. J. (1984). Adverse Reactions to Psychedelic Drugs: A Review of the Literature. The Journal of Nervous and Mental Disease, 172(10), 577-595. PMID: 6384428
  5. 1P-LSD (Google Trends) | https://trends.google.com/trends/explore?q=1p-lsd
  6. Brandt, S. D. (2015, October 12). Return of the lysergamides. Part I: Analytical and behavioral characterization of 1‐propionyl‐d‐lysergic acid diethylamide (1P‐LSD). https://doi.org/10.1002/dta.1884
  7. Cooper, D. A. (1988, March). Future synthetic drugs of abuse. In Proceedings of the international symposium on the forensic aspects of controlled substances: March (Vol. 28, p. 79). https://www.erowid.org/library/books_online/future_synthetic/future_synthetic.shtml
  8. Kman1898. (2015, February 16). The Big & Dandy 1P-LSD Thread, Volume 1 - Page 4. Retrieved from https://www.bluelight.org/vb/threads/745848?p=12880348&viewfull=1#post12880348
  9. Potentiation of MDMA‐induced toxicity by ... d‐lysergic acid diethylamide (LSD) | https://onlinelibrary.wiley.com/doi/abs/10.1002/nrc.20023
  10. Potentiation of MDMA-induced dopamine release and serotonin neurotoxicity by 5-HT2 receptor agonists | https://indiana.pure.elsevier.com/en/publications/potentiation-of-34-methylenedioxymethamphetamine-induced-dopamine
  11. Ecstasy induces apoptosis via 5-HT(2A)-receptor stimulation in cortical neurons. | https://www.ncbi.nlm.nih.gov/pubmed/17572501
  12. Passie, T., Halpern, J. H., Stichtenoth, D. O., Emrich, H. M., & Hintzen, A. (2008). The Pharmacology of Lysergic Acid Diethylamide: A Review, 14, 295–314. https://doi.org/10.1111/j.1755-5949.2008.00059.x
  13. https://erowid.org/chemicals/lsd/lsd_interactions.shtml | LSD Interactions by Erowid
  14. Wanderli. "A Nice Little Trip to the Hospital: An Experience with Lithium & LSD (ID 83935)". Erowid.org. Oct 3, 2010.
  15. MissDja1a. "Having a Seizure and Passing Out: An Experience with Lithium & LSD (ID 75153)". Erowid.org. Dec 16, 2008.
  16. Reddit account of seizure on LSD + Lithium | https://www.reddit.com/r/Psychonaut/comments/17uspp/please_read_a_cautionary_tale_concerning_lsd/
  17. Tripsit Factsheets - LSD | http://drugs.tripsit.me/lsd
  18. Talaie, H., Panahandeh, R., Fayaznouri, M. R., Asadi, Z., & Abdollahi, M. (2009). Dose-independent occurrence of seizure with tramadol. Journal of Medical Toxicology, 5(2), 63-67. https://doi.org/10.1007/BF03161089
  19. Tripsit Factsheets - LSD | http://drugs.tripsit.me/lsd
  20. Fisher, D. D., & Ungerleider, J. T. (1967). Grand mal seizures following ingestion of LSD. California Medicine, 106(3), 210. PMCID: PMC1502729
  21. Question ID: 2837 (Ask Erowid) | https://www.erowid.org/ask/ask.php?ID=2837
  22. Synthetic drugs: new law to combat "legal highs" | https://derstandard.at/1317018702282/Kraeutermischungen-Synthetische-Drogen-Neues-Gesetz-soll-Legal-Highs-bekaempfen
  23. New Psychoactive Substances Act (NPSG) | https://www.parlament.gv.at/PAKT/VHG/XXIV/ME/ME_00317/imfname_231611.pdf
  24. Noteikumi par Latvijā kontrolējamajām narkotiskajām vielām, psihotropajām vielām un prekursoriem (2.4.punkts) | http://likumi.lv/doc.php?id=121086
  25. (in Swedish) Folkhälsomyndigheten. | https://www.folkhalsomyndigheten.se/nyheter-och-press/nyhetsarkiv/2016/januari/31-nya-substanser-klassas-som-narkotika-eller-halsofarlig-vara/
  26. Verordnung des EDI über die Verzeichnisse der Betäubungsmittel, psychotropen Stoffe, Vorläuferstoffe und Hilfschemikalien | http://web.archive.org/web/20170329020935/https://www.admin.ch/opc/de/classified-compilation/20101220/index.html
  27. Psychoactive Substances Act 2016 (Legislation.gov.uk) | http://www.legislation.gov.uk/ukpga/2016/2/contents/enacted